CR20200382A - Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano - Google Patents

Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Info

Publication number
CR20200382A
CR20200382A CR20200382A CR20200382A CR20200382A CR 20200382 A CR20200382 A CR 20200382A CR 20200382 A CR20200382 A CR 20200382A CR 20200382 A CR20200382 A CR 20200382A CR 20200382 A CR20200382 A CR 20200382A
Authority
CR
Costa Rica
Prior art keywords
sting
stimulator
cyclopentane
interferon genes
based modulators
Prior art date
Application number
CR20200382A
Other languages
English (en)
Spanish (es)
Inventor
Andrew Fensome
Martin James Wythes
Ketan S Gajiwala
Andreas Maderna
Eugene Yuanjin Rui
Indrawan James Mcalpine
Ryan Patman
Mehran Jalaie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of CR20200382A publication Critical patent/CR20200382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65744—Esters of oxyacids of phosphorus condensed with carbocyclic or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CR20200382A 2018-03-15 2019-03-12 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano CR20200382A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862643467P 2018-03-15 2018-03-15
US201862666204P 2018-05-03 2018-05-03
US201862742532P 2018-10-08 2018-10-08
US201962809990P 2019-02-25 2019-02-25
PCT/IB2019/052009 WO2019175776A1 (en) 2018-03-15 2019-03-12 Cyclopentane-based modulators of sting (stimulator of interferon genes)

Publications (1)

Publication Number Publication Date
CR20200382A true CR20200382A (es) 2020-12-10

Family

ID=66103038

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200382A CR20200382A (es) 2018-03-15 2019-03-12 Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano

Country Status (25)

Country Link
US (4) US10538542B2 (cg-RX-API-DMAC7.html)
EP (1) EP3765474B1 (cg-RX-API-DMAC7.html)
JP (1) JP7266942B2 (cg-RX-API-DMAC7.html)
KR (1) KR20200131878A (cg-RX-API-DMAC7.html)
CN (1) CN111918871A (cg-RX-API-DMAC7.html)
AU (1) AU2019234043A1 (cg-RX-API-DMAC7.html)
BR (1) BR112020018593A2 (cg-RX-API-DMAC7.html)
CA (1) CA3093631C (cg-RX-API-DMAC7.html)
CL (1) CL2020002352A1 (cg-RX-API-DMAC7.html)
CR (1) CR20200382A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000160A (cg-RX-API-DMAC7.html)
EC (1) ECSP20057847A (cg-RX-API-DMAC7.html)
ES (1) ES2923298T3 (cg-RX-API-DMAC7.html)
IL (1) IL277278A (cg-RX-API-DMAC7.html)
MA (1) MA52012A (cg-RX-API-DMAC7.html)
MX (1) MX2020009587A (cg-RX-API-DMAC7.html)
NI (1) NI202000058A (cg-RX-API-DMAC7.html)
PE (1) PE20210412A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551486A1 (cg-RX-API-DMAC7.html)
PY (1) PY1919127A (cg-RX-API-DMAC7.html)
RU (1) RU2020130048A (cg-RX-API-DMAC7.html)
SG (1) SG11202008102VA (cg-RX-API-DMAC7.html)
TW (1) TWI741268B (cg-RX-API-DMAC7.html)
UY (1) UY38145A (cg-RX-API-DMAC7.html)
WO (1) WO2019175776A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
JP7037667B2 (ja) 2017-12-20 2022-03-16 インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール,ヴイ.ヴイ.アイ. Stingアダプタータンパク質を活性化するホスホン酸結合を有する3’3’環状ジヌクレオチド
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202028179A (zh) 2018-10-08 2020-08-01 美商普萊恩醫療公司 胺基酸化合物及使用方法
PH12022550709A1 (en) * 2019-09-25 2023-03-27 Pfizer Polyheterocyclic modulators of sting (stimulator of interferon genes)
US20230141284A1 (en) 2020-04-10 2023-05-11 Ono Pharmaceutical Co., Ltd. Cancer therapeutic method
EP4259642A1 (en) * 2020-12-08 2023-10-18 F. Hoffmann-La Roche AG Novel synthesis of phosphorodithioate oligonucleotides
US11964978B2 (en) * 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
EP3152217B1 (en) 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
US10538542B2 (en) * 2018-03-15 2020-01-21 Pfizer Inc. Cyclopentane-based modulators of STING (stimulator of interferon genes)

Also Published As

Publication number Publication date
ECSP20057847A (es) 2021-04-29
KR20200131878A (ko) 2020-11-24
PE20210412A1 (es) 2021-03-04
WO2019175776A1 (en) 2019-09-19
JP7266942B2 (ja) 2023-05-01
US10538542B2 (en) 2020-01-21
MX2020009587A (es) 2020-10-05
EP3765474A1 (en) 2021-01-20
US10968242B2 (en) 2021-04-06
PH12020551486A1 (en) 2021-08-23
US20190284216A1 (en) 2019-09-19
PY1919127A (es) 2020-08-26
CA3093631A1 (en) 2019-09-19
CA3093631C (en) 2023-01-24
ES2923298T3 (es) 2022-09-26
RU2020130048A (ru) 2022-04-15
CN111918871A (zh) 2020-11-10
TWI741268B (zh) 2021-10-01
US20200102334A1 (en) 2020-04-02
CL2020002352A1 (es) 2020-12-18
IL277278A (en) 2020-10-29
MA52012A (fr) 2021-01-20
NI202000058A (es) 2021-01-08
BR112020018593A2 (pt) 2020-12-29
AU2019234043A1 (en) 2020-09-17
US20230382932A1 (en) 2023-11-30
DOP2020000160A (es) 2020-09-30
JP2021518335A (ja) 2021-08-02
SG11202008102VA (en) 2020-09-29
UY38145A (es) 2019-10-31
TW201945036A (zh) 2019-12-01
EP3765474B1 (en) 2022-06-15
RU2020130048A3 (cg-RX-API-DMAC7.html) 2022-04-15
US20210230196A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
DOP2022000066A (es) Moduladores de sting (estimulador de genes de interferón)
CL2020002352A1 (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
CL2021002104A1 (es) Compuestos, composiciones y métodos.
PY2240956A (es) Nuevos Compuestos bicíclicos y sus usos
CO2020001220A2 (es) Compuestos, composiciones y métodos
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
PE20241068A1 (es) Moduladores de profarmacos de la via de estres integrada
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
CL2017001932A1 (es) Dinucleotidos cíclicos útiles para el tratamiento de cancer entre otros.
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MX2020010999A (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos.
CO2018000224A2 (es) Compuestos inhibidores de la señalización de la vía de notch
MX2021015188A (es) Moduladores de nueva generacion del estimulador de genes de interferon (sting).
UY37941A (es) Derivados de bencimidazol y sus usos
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
CU20190042A7 (es) Compuestos derivados de naftiridinona
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
ECSP20080991A (es) Compuestos de cianotriazol y usos de los mismos
PE20181450A1 (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
AR119317A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
AR099767A1 (es) Derivados del ácido acético azaindol y su uso como moduladores del receptor de prostaglandina d2
UY37166A (es) Nucleósidos ánalogos de alquinilo como inhibidores de rinovirus humano
AR122310A1 (es) Moduladores de sting (estimulador de genes de interferón)
AR114263A1 (es) Compuestos terapéuticos y métodos para utilizarlos